992 related articles for article (PubMed ID: 27567210)
1. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
2. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Ă–zdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
3. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
4. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
Grivas P; Yu EY
Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
[TBL] [Abstract][Full Text] [Related]
5. Biomarker development in the context of urologic cancers.
Kelloff GJ; Sigman CC; Scher HI
Urol Oncol; 2015 Jun; 33(6):295-301. PubMed ID: 25746942
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
7. Emerging critical role of molecular testing in diagnostic genitourinary pathology.
Netto GJ; Cheng L
Arch Pathol Lab Med; 2012 Apr; 136(4):372-90. PubMed ID: 22458900
[TBL] [Abstract][Full Text] [Related]
8. Biomarker, Molecular, and Technologic Advances in Urologic Pathology, Oncology, and Imaging.
Ellis CL; Harik LR; Cohen C; Osunkoya AO
Arch Pathol Lab Med; 2017 Apr; 141(4):499-516. PubMed ID: 28157406
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
Jones RT; Felsenstein KM; Theodorescu D
Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
[TBL] [Abstract][Full Text] [Related]
10. Precision Medicine in Gastrointestinal Pathology.
Wang DH; Park JY
Arch Pathol Lab Med; 2016 May; 140(5):449-60. PubMed ID: 27128302
[TBL] [Abstract][Full Text] [Related]
11. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
12. Targeting molecular aberrations in urothelial carcinoma: are we almost there?
Apolo AB; Kwiatkowski DJ
Am Soc Clin Oncol Educ Book; 2013; ():195-9. PubMed ID: 23714499
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
14. The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.
Lin VTG; Yang ES
J Natl Cancer Inst; 2019 Oct; 111(10):1016-1022. PubMed ID: 31165154
[TBL] [Abstract][Full Text] [Related]
15. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
16. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
19. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.
Chae YK; Pan AP; Davis AA; Patel SP; Carneiro BA; Kurzrock R; Giles FJ
Mol Cancer Ther; 2017 Dec; 16(12):2645-2655. PubMed ID: 29203694
[TBL] [Abstract][Full Text] [Related]
20. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]